6 October 2015 - Arnuity Ellipta (fluticasone furoate dry powder for oral inhalation) has been approved in Canada as a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of steroid-responsive bronchial asthma in patients aged 12 years and older.

The approved strengths are Arnuity Ellipta 100 mcg and 200 mcg. Arnuity is administered once daily via the dry powder inhaler called Ellipta, which is also used across a range of other approved respiratory medicines in the GSK portfolio.

Sally Taylor, Country Medical Officer, Canada said: "Arnuity Ellipta a GSK asthma treatment approved in Canada, provides physicians with a once-daily treatment option delivered via the ELLIPTA® inhaler to meet the needs of appropriate patients aged 12 and above."

For more details, go to: http://news.morningstar.com/all/canada-news-wire/20150929C6042/gsk-receives-approval-for-arnuity-ellipta-fluticasone-furoate-in-canada-for-the-treatment-of-asthma.aspx